EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery

Cecile Riviere-Cazaux iD, Christopher J Graser, Arthur E Warrington, Matthew D Hoplin, Katherine M Andersen, Noor Malik, Elizabeth A Palmer, Lucas P Carlstrom, Surendra Dasari, Amanda Munoz-Casabella, Samar Ikram, Keyvan Ghadimi und 11 weitere

Neuro-Oncology · 15.05.2025 · 27 (4) · 948-962

DOI: 10.1093/neuonc/noae277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 30.12.2024. Verfasst von Cecile Riviere-Cazaux und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Biomarkers, Tumor, Glioma, Proteome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Ivy Foundation, Brains Together for the Cure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown.

Methods

Aptamer-based proteomics was performed on 147 CSF samples from 74 patients; 71 of whom had grade 2–4 astrocytomas or grade 2–3 oligodendrogliomas. This included pre- versus post-resection intracranial CSF samples obtained at early (1–16 days; n = 20 patients) or delayed (86–153 days; n = 11 patients) time points for patients with glioma. Paired lumbar versus intracranial glioma CSF samples were also obtained (n = 14 patients).

Results

Significant differences were identified in the CSF proteome between lumbar, subarachnoid, and ventricular CSF in patients with gliomas. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome, with distinct sets of proteins present at different time points since resection. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, such as bevacizumab and immunotherapies.

Conclusions

The intracranial glioma CSF proteome serves as a rich and dynamic reservoir of potential biomarkers that can be used to evaluate the effects of resection and other therapies over time. All data within this study, including detailed individual clinical annotations, are shared as a resource for the neuro-oncology community to collectively address these unanswered questions and further understand glioma biology through CSF proteomics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBiomarkers, TumorGliomaProteomeHumansFemaleMaleMiddle AgedProteomicsAdultAgedYoung AdultPrognosisFollow-Up Studies

Stichwörter der Autor:innen

biomarker | cerebrospinal fluid | glioma | monitoring | proteomics

Substanzen

Biomarkers, TumorProteome

Autor:innen und Institutionen

  • Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA.
  • Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Cecile Riviere-Cazaux, Jann N Sarkaria, Jamie J Van Gompel

Förderung

  • NINDS NIH HHS
  • Ivy Foundation
  • Brains Together for the Cure
  • NCI NIH HHS
  • Humor to fight the Tumor
  • Mayo Clinic Center for Individualized Medicine
  • NIGMS NIH HHS
  • Merck Pharmaceuticals

Zitieren

APA

Riviere-Cazaux, C., Graser, C. J., Warrington, A. E., Hoplin, M. D., Andersen, K. M., Malik, N., Palmer, E. A., Carlstrom, L. P., Dasari, S., Munoz-Casabella, A., Ikram, S., Ghadimi, K., Himes, B. T., Jusue-Torres, I., Sarkaria, J. N., Meyer, F. B., Van Gompel, J. J., Kizilbash, S. H., Sener, U., …, & Burns, T. C. (2025). A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery. Neuro-Oncology, 27(4), 948-962. https://doi.org/10.1093/neuonc/noae277

Vancouver

Riviere-Cazaux C, Graser CJ, Warrington AE, Hoplin MD, Andersen KM, Malik N, et al. A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery. Neuro-Oncology. 2025;27(4):948-962. doi:10.1093/neuonc/noae277

BibTeX
@article{RiviereCazaux2025,
  author = {Riviere-Cazaux, Cecile and Graser, Christopher J and Warrington, Arthur E and Hoplin, Matthew D and Andersen, Katherine M and Malik, Noor and Palmer, Elizabeth A and Carlstrom, Lucas P and Dasari, Surendra and Munoz-Casabella, Amanda and Ikram, Samar and Ghadimi, Keyvan and Himes, Benjamin T and Jusue-Torres, Ignacio and Sarkaria, Jann N and Meyer, Fredric B and Van Gompel, Jamie J and Kizilbash, Sani H and Sener, Ugur and Michor, Franziska and Campian, Jian L and Parney, Ian F and Burns, Terry C},
  title = {A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {948--962},
  doi = {10.1093/neuonc/noae277}
}
Kostenlos starten →